Small molecule protein synthesis modulators
The present disclosure provides compounds, and pharmaceutically acceptable salts thereof, which are useful for modulating protein synthesis. The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts thereof, and methods of treating or preventing diseases or disorders (e.g., diseases or disorders associated with BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D) by administering to a subject in need thereof the compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof.
1 . A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
2 . The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
3 . The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
4 . The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
5 . The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
6 . The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
7 . The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
8 . The compound of claim 1 , wherein the compound is:
9 . The compound of claim 1 , wherein the compound is:
10 . The compound of claim 1 , wherein the compound is:
11 . The compound of claim 1 , wherein the compound is:
12 . The compound of claim 1 , wherein the compound is:
13 . The compound of claim 1 , wherein the compound is:
14 . A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
15 . A method of modulating protein synthesis in a subject in need thereof or in a cell, tissue, or biological sample, comprising administering to the subject in need thereof or contacting the cell, tissue, or biological sample with an effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.
16 . A method of decreasing protein synthesis in a subject in need thereof or in a cell, tissue, or biological sample, comprising administering to the subject in need thereof or contacting the cell, tissue, or biological sample with an effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.
17 . A method comprising administering to a subject the compound of claim 1 , or a pharmaceutically acceptable salt thereof.
18 . A method of treating a disease in a subject in need thereof, comprising administering to the subject in need thereof an effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the disease is:
a. associated with B-cell lymphoma 2 (BCL-2), MYC proto-oncogene bHLH transcription factor (MYC), cyclin D1 (CCND1), myeloid cell leukemia 1 (MCL-1), anaplastic lymphoma kinase (ALK), or GTPase KRas G12D mutant (KRAS-G12D);
b. a cancer selected from prostate cancer, pancreatic cancer, lung cancer, breast cancer, colorectal cancer, endometrial cancer, ovarian cancer, cervical cancer, esophageal cancer, bladder cancer, biliary cancer, hematopoietic cancer, and neuroblastoma;
c. a neurological disease selected from cerebellar ataxia and a neurodegenerative disease; or
d. an immune disorder selected from psoriasis, lupus, and rheumatoid arthritis.
19 . The method of claim 18 , wherein the disease is associated with B-cell lymphoma 2 (BCL-2), MYC proto-oncogene bHLH transcription factor (MYC), cyclin D1 (CCND1), myeloid cell leukemia 1 (MCL-1), anaplastic lymphoma kinase (ALK), or GTPase KRas G12D mutant (KRAS-G12D).
20 . The method of claim 18 , wherein the disease is:
a cancer selected from prostate cancer, pancreatic cancer, lung cancer, breast cancer, colorectal cancer, endometrial cancer, ovarian cancer, cervical cancer, esophageal cancer, bladder cancer, biliary cancer, hematopoietic cancer, and neuroblastoma;
a neurological disease selected from cerebellar ataxia and a neurodegenerative disease; or
an immune disorder selected from psoriasis, lupus, and rheumatoid arthritis.
21 . A kit comprising:
the compound of claim 1 , or a pharmaceutically acceptable salt thereof; and
instructions for use of the compound, or pharmaceutically acceptable salt thereof.